



# Effective Initiation and Treatment With Basal Insulin in People With Type 2 Diabetes: Focus on Mitigating Hypoglycemia in Patients at Increased Risk: Executive Summary

John Anderson, Scott Urquhart, Geralyn Spollett, and Paresh Dandona

Many people with type 2 diabetes are treated with insulin with the goal of achieving a specific A1C target. The most prominent risk for people on insulin therapy is hypoglycemia. When basal insulin analogs are used appropriately, the risk of hypoglycemia can be reduced while still achieving individualized glycemic goals.

In a series of short videos now available on the *Clinical Diabetes* website, the authors discuss approaches to optimizing basal insulin initiation and treatment in people with type 2 diabetes, including those at high risk such as individuals with renal impairment and older adults, with a focus on reaching A1C goals while mitigating the risk for hypoglycemia.

This article is intended to briefly summarize those discussions, and readers are encouraged to view the videos in their entirety at <https://clinical.diabetesjournals.org/content/basal-insulin-videos>.

## Video Summaries

**Introduction (Available at <https://bcove.video/2Q2Rb9b>)**

Approximately 50% of people with type 2 diabetes have poorly controlled disease and are vulnerable to long-term micro- and macrovascular complications (1). As type 2 diabetes progresses, many patients will require insulin

to maintain glycemic control. The appropriate use of insulin requires a balance between the need for tight glucose control and the potential risk for hypoglycemia. Definitions of hypoglycemia have evolved over time, and the American Diabetes Association (ADA) now uses a three-level classification of hypoglycemia severity (2). Mitigating the risk for hypoglycemia is crucial to the successful treatment of people with type 2 diabetes. In the following series of videos, the authors discuss the use of available insulin formulations in the context of hypoglycemia risk.

**Basal Insulin Therapy—Balancing Glycemic Control With Risk for Hypoglycemia (Available at <https://bcove.video/3h3Y85h>)**

The achievement of tight glycemic control reduces micro- and macrovascular complications, and adherence to treatment improves quality of life and decreases health care costs (3–9). The authors discuss the association between A1C reduction and microvascular complications, as reported in the UK Prospective Diabetes Study (9).

Using insulin therapies to achieve tight glycemic control can place people at risk for hypoglycemia. The importance of educating patients on how to avoid hypoglycemia while maintaining glycemic control is also highlighted, including teaching patients how to appropriately titrate insulin. People with diabetes should also be encouraged to monitor their blood glucose levels, particularly while titrating their antidiabetic therapies, and to communicate their results to their health care providers (HCPs).

Fear of hypoglycemia on the part of either the patient or the HCP can affect treatment decisions and adherence to therapy (10). The authors review published evidence from a retrospective cohort study demonstrating that, in patients with type 2 diabetes, improved adherence to insulin treatment reduces the likelihood of emergency room visits and hospitalizations resulting from hypoglycemia (11).

Major advances in the development of insulin therapies have occurred throughout the past century, from the discovery of insulin in 1921 (12) to the recent development of the second-generation basal insulin analogs insulin glargine 300 units/mL (Gla-300) and insulin degludec (IDeg). Both of these basal insulin formulations enable more effective glycemic control and provide stable

Corresponding author: John Anderson, [JohnAnderson1@hcahealthcare.com](mailto:JohnAnderson1@hcahealthcare.com)  
<https://doi.org/10.2337/cd20-0035>

©2020 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <https://www.diabetesjournals.org/content/license>.

and predictable insulin levels throughout a period of at least 24 hours, with a lower risk for hypoglycemia (13).

***Identifying and Managing Patients at Increased Risk for Hypoglycemia (Available at <https://bcove.video/32whg7M>)***

It is crucial to identify people who are at elevated risk for developing hypoglycemia, including those for whom a long duration of type 2 diabetes or complexity of their treatments can impair the ability to perceive hypoglycemia (14). The presence of certain comorbidities such as chronic kidney disease (CKD) and cardiovascular disease (CVD) in people with type 2 diabetes can predispose them to developing hypoglycemia (14). The authors explain that people with CKD and those who are undergoing dialysis are particularly vulnerable because the half-life of insulin is markedly protracted in this population.

Some medications can increase the risk for developing hypoglycemia, and others can mask its symptoms. The authors review several important considerations for managing hypoglycemia risk, including medical nutrition therapy, appropriate selection of glycemic targets, hypoglycemia awareness, patient–HCP communication, and blood glucose monitoring (2,15). For people receiving basal insulin, it is important to provide a clear titration schedule and to both optimize and simplify the treatment regimen as appropriate (1,16). The authors emphasize that the appropriate selection of basal insulin is important in achieving predictable, stable glycemic control.

***Differences Between First- and Second-Generation Basal Insulin Therapies (Available at <https://bcove.video/39etT9f>)***

As the development of insulin formulations has evolved from NPH through first-generation basal insulin analogs (insulin glargine 100 units/mL [Gla-100] and insulin detemir) and then to second-generation basal insulin analogs (Gla-300 and IDeg), clinicians now have access to basal insulins with much more stable and prolonged pharmacokinetic profiles and with a lower risk of hypoglycemia (12,17–19). The authors discuss the importance of reducing the risk for hypoglycemia and note that emergency room visits and hospitalizations as a result of hypoglycemia can incur large costs (20) and are largely preventable.

The authors also explain the differences between randomized controlled trials (RCTs) and real-world studies that assess drug effects in people in everyday clinical practice and comprise a broader group of participants,

including those at high risk or who may otherwise be excluded from RCTs because of various comorbidities.

The authors summarize the results of the retrospective real-world DELIVER-2 study ( $n = 6,033$ ) that demonstrated cost savings of \$1,439/year per patient associated with a reduction in all hypoglycemia-related health care resource utilization when switching from the patients' current insulin to Gla-300 versus switching to another basal insulin analog (21). They also review results of the randomized, pragmatic real-world ACHIEVE Control trial ( $n = 3,304$ ), which showed superiority with Gla-300 versus first-generation basal insulin analogs for achievement of a 6-month composite end point of HEDIS (Healthcare Effectiveness Data and Information Set) A1C target attainment without documented symptomatic ( $\leq 70$  mg/dL) or severe (defined as ADA level 3) hypoglycemia at any time of day (22). The authors note that, across several RCTs and real-world studies of people with type 2 diabetes and increased risk for hypoglycemia (e.g., those  $\geq 65$  years of age, with renal impairment, or with CVD) lower rates of hypoglycemia were seen with second-generation basal insulin analogs (Gla-300 and IDeg) versus first-generation basal insulin analogs (23–27) and were consistent with results from RCTs in the overall population with type 2 diabetes.

The authors conclude this video by summarizing results from RCTs such as the EDITION meta-analysis ( $n = 2,737$ ) that evaluated Gla-100 versus Gla-300 and showed a consistent benefit of Gla-300 with regard to hypoglycemia risk (28). The authors also discuss the results of the BEGIN research program ( $n = 3,386$ ), which evaluated IDeg versus Gla-100 and showed a benefit of IDeg with regard to nocturnal hypoglycemia, but not to overall incidence of hypoglycemia (28).

***Comparison of Second-Generation Basal Insulin Analogs (Available at <https://bcove.video/3915xiS>)***

Although both Gla-300 and IDeg provide stable insulin concentrations for more than 24 hours, they have unique mechanistic differences; Gla-300 is released freely into the circulation from microprecipitates, whereas IDeg, once injected, forms large multihexameric complexes in the subcutaneous tissue and binds to albumin in circulation (29–33).

Few studies have compared the efficacy and safety of Gla-300 and IDeg in insulin-naïve patients. The authors discuss the results from the BRIGHT RCT ( $n = 929$ ), which demonstrated similar efficacy and safety of Gla-300 and IDeg throughout 24 weeks, with a lower risk of hypoglycemia with Gla-300 during the initial 12-week titration

period versus IDeg (34). In the real-world DELIVER Naïve D study ( $n = 1,276$ ), the efficacy and safety of Gla-300 and IDeg, including risks of hypoglycemia, were generally comparable (35). In the CONFIRM study ( $n = 4,056$ ), a lower risk of pre- versus post-treatment hypoglycemia was seen with IDeg than with Gla-300 (36), although the rate of hypoglycemia at baseline between the two groups was not balanced.

Studies comparing the efficacy and safety of IDeg and Gla-300 in people at increased risk for developing hypoglycemia have also been conducted. For example, in the CONCLUDE trial ( $n = 1,609$ ), a similar risk of hypoglycemia was observed with IDeg and Gla-300 (37). The authors review a subgroup analysis of the BRIGHT trial ( $n = 929$ ) in patients with type 2 diabetes and renal impairment (estimated glomerular filtration rate  $<60$  mL/min/1.73 m<sup>2</sup>), which showed greater reductions in A1C with Gla-300 than with IDeg, with similar rates of hypoglycemia (38). Although the results of these subgroup analyses are informative, further studies are needed to confirm them.

#### ACKNOWLEDGMENTS

The production of this video series and associated materials was funded by Sanofi US, Inc., in Bridgewater, NJ. The authors received writing/editorial support in the preparation of this digital manuscript and executive summary from Karen Pemberton and Leah Bernstein, on behalf of Evidence Scientific Solutions in Philadelphia, PA. This assistance was also funded by Sanofi US, Inc.

#### REFERENCES

1. Philis-Tsimikas A. Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control. *Am J Med* 2013;126(Suppl. 1):S21–S27
2. American Diabetes Association. 2. Classification and diagnosis of diabetes: *Standards of Medical Care in Diabetes—2020*. *Diabetes Care* 2020;43(Suppl. 1):S14–S31
3. Dalal MR, Kazemi M, Ye F, Xie L. Hypoglycemia after initiation of basal insulin in patients with type 2 diabetes in the United States: implications for treatment discontinuation and healthcare costs and utilization. *Adv Ther* 2017;34:2083–2092
4. Dalal MR, Kazemi MR, Ye F. Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization. *Curr Med Res Opin* 2017;33:209–214
5. Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. *J Med Econ* 2011;14:646–655
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359:1577–1589
7. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and

- its key contributors. *Patient Prefer Adherence* 2016;10:1299–1307
8. Seaquist ER, Anderson J, Childs B, et al.; American Diabetes Association; Endocrine Society. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. *J Clin Endocrinol Metab* 2013;98:1845–1859
9. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000;321:405–412
10. Berard L, Bonnemaire M, Mical M, Edelman S. Insights into optimal basal insulin titration in type 2 diabetes: results of a quantitative survey. *Diabetes Obes Metab* 2018;20:301–308
11. Perez-Nieves M, Boye KS, Kiljanski J, Cao D, Lage MJ. Adherence to basal insulin therapy among people with type 2 diabetes: a retrospective cohort study of costs and patient outcomes. *Diabetes Ther* 2018;9:1099–1111
12. Vecchio I, Tornali C, Bragazzi NL, Martini M. The discovery of insulin: an important milestone in the history of medicine. *Front Endocrinol (Lausanne)* 2018;9:613
13. Cheng AYY, Patel DK, Reid TS, Wyne K. Differentiating basal insulin preparations: understanding how they work explains why they are different. *Adv Ther* 2019;36:1018–1030
14. Silbert R, Salcido-Montenegro A, Rodriguez-Gutierrez R, Katabi A, McCoy RG. Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies. *Curr Diab Rep* 2018;18:53
15. Tomky D. Detection, prevention, and treatment of hypoglycemia in the hospital. *Diabetes Spectr* 2005;18:39–44
16. International Hypoglycaemia Study Group. Minimizing hypoglycemia in diabetes. *Diabetes Care* 2015;38:1583–1591
17. Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 Units · mL<sup>-1</sup> provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL<sup>-1</sup>. *Diabetes Care* 2015;38:637–643
18. Flood TM. Appropriate use of insulin analogs in an increasingly complex type 2 diabetes mellitus (T2DM) landscape. *J Fam Pract* 2007;56(Suppl.):S1–S10; quiz S11–S12
19. Hirsch IB. Insulin analogues. *N Engl J Med* 2005;352:174–183
20. Kahn PA, Wagner NE, Gabbay RA. Underutilization of glucagon in the prehospital setting. *Ann Intern Med* 2018;168:603–604
21. Zhou FL, Ye F, Berhanu P, et al. Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin. *Diabetes Obes Metab* 2018;20:1293–1297
22. Meneghini LF, Sullivan SD, Oster G, et al. A pragmatic randomized prospective clinical trial of insulin glargine 300 U/mL (Gla-300) versus other basal insulins in insulin-naïve patients with type 2 diabetes. Oral presentation at the Academy of Managed Care Pharmacy (AMCP) Nexus, 22–25 October 2018, Orlando, FL

23. Javier Escalada F, Halimi S, Senior PA, et al. Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment. *Diabetes Obes Metab* 2018;20:2860–2868
24. Marso SP, McGuire DK, Zinman B, et al.; DEVOTE Study Group. Efficacy and safety of degludec versus glargine in type 2 diabetes. *N Engl J Med* 2017;377:723–732
25. Ritzel R, Harris SB, Baron H, et al. A randomized controlled trial comparing efficacy and safety of insulin glargine 300 units/mL versus 100 units/mL in older people with type 2 diabetes: results from the SENIOR study. *Diabetes Care* 2018;41:1672–1680
26. Sullivan SD, Freemantle N, Menon AA, et al. High-hypoglycemia-risk patients with type 2 diabetes on first-generation basal insulins (BIs) in the US have a lower risk of hypoglycemia after 1 year following switch to insulin glargine 300 U/mL versus first-generation BIs (DELIVER – High Risk). Poster presented at American Diabetes Association’s 79th Scientific Session, 7–11 June 2019, San Francisco, CA
27. Yale JF, Aroda VR, Charbonnel B, et al. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: a patient-level meta-analysis examining older and younger adults with type 2 diabetes. *Diabetes Metab* 2020;46:110–118
28. Rousset R, Ritzel R, Boëlle-Le Corfec E, Balkau B, Rosenstock J. Clinical perspectives from the BEGIN and EDITION programmes: trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM. *Diabetes Metab* 2018;44:402–409
29. Bailey TS, Pettus J, Rousset R, et al. Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes. *Diabetes Metab* 2018;44:15–21
30. Hompesch M, Patel DK, LaSalle JR, Bolli GB. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes. *Postgrad Med* 2019;131:117–128
31. Adams GG, Alzahrani Q, Jiwani SI, et al. Glargine and degludec: solution behaviour of higher dose synthetic insulins. *Sci Rep* 2017;7:7287
32. Heise T, Kaplan K, Haahr HL. Day-to-day and within-day variability in glucose-lowering effect between insulin degludec and insulin glargine (100 U/mL and 300 U/mL): a comparison across studies. *J Diabetes Sci Technol* 2018;12:356–363
33. Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S, Haahr HL. Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. *Diabetes Obes Metab* 2017;19:1032–1039
34. Rosenstock J, Cheng A, Ritzel R, et al. More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naïve type 2 diabetes: the randomized head-to-head BRIGHT trial. *Diabetes Care* 2018;41:2147–2154
35. Sullivan SD, Nicholls CJ, Gupta RA, et al. Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: the DELIVER Naïve D real-world study. *Diabetes Obes Metab* 2019;21:2123–2132
36. Tibaldi J, Hadley-Brown M, Liebl A, et al. A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes. *Diabetes Obes Metab* 2019;21:1001–1009
37. Philis-Tsimikas A, Klonoff DC, Khunti K, et al. Reduced risk of hypoglycaemia and lower HbA1c with degludec compared to glargine U300 in insulin-treated patients with type 2 diabetes. Oral presentation at the European Association for the Study of Diabetes Congress, 16–20 September 2019, Barcelona, Spain
38. Haluzík M, Cheng A, Müller-Wieland D, et al. Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: a subanalysis from the BRIGHT trial. *Diabetes Obes Metab* 2020;22:1369–1377